AASOG National Conference 2014 - September 19-20, Ohio

We are pleased  to announce the AASOG National Conference 2014 on Sarcoidosis Health Care Disparities and Clinical Research Challenges, which will be held in Ohio, September 19-20, 2014. Programme details & Registration

ILD Conference 2014 Presentation and Abstracts online

We are pleased to ainform you that the ILDs Conference presentations as well as Posters Abstracts have been published at the Conference website: http://www.ildprague2014.com/presentations.


The 3rd combined WASOG and BAL meeting will be held in Turkey on 8-11 October 2014. On behalf of the WASOG and Turkish Thoracic Society we are pleased to invite you to the congress. The congress will be held in Kusadasi which is a resort town near Izmir and ancient Ephesus. Abstract submission deadline: August 25th!!

For details visit the official congress website at http://www.wasogbal2014.org.

The FSR Physicians’ Treatment Protocol

FSR (Foundation for Sarcoidosis Research) is committed to addressing the gaps that exist in sarcoidosis research. This includes the lack of information and knowledge around the current disease treatment options. Yet another challenge of “rare disease” is the inherent rarity of specialists and experts that can help guide treatment options. While physicians who specialize in sarcoidosis can be found, many times patients and doctors are challenged by a lack of information. FSR’s Scientific Advisory Board developed a mobile-friendly Physicians’ Treatment Protocol that can offer expert information to physicians to help guide their diagnosis and treatment decisions.

Pulmonary Sarcoidosis: A Guide for the Practicing Clinician

Pulmonary Sarcoidosis: A Guide for the Practicing Clinician is a valuable resource for clinicians of varied disciplines concerning the care of the sarcoidosis patient. Chapters are written by distinguished authors who have extensive experience in caring for these patients. This guide is fully comprehensive and evidence-based and will be an essential addition to the bookshelves of all whose practice involves the care and treatment of patients with sarcoidosis. More details & order online

MTX app for iPhone, iPad & Android

This app provides recommendations for the use of methotrexate in sarcoidosis and everything else you need to know about methotrexate. The app was developed on behalf of WASOG and is now available for iOS and Android. Details & Download

Follow WASOG on LinkedIn, Twitter and via our e-Newsletter

In addition to this website WASOG will keep you informed using several media. Updates include WASOG news, conference updates and other relevant information we would like to share with you. We therefore invitite you to subscribe to our e-Newsletter and/or follow @wasog on Twitter. You may also join our group on LinkedIn to expand your professional network and participate in discussions.

Sarcoidosis and other ild around the world

To inform you about sarcoidosis and other ild in different countries we ask(ed) colleagues to summarize the prevalence, the research and important websites, etc. This topic has been added to the WASOG site. Read more


Highlighted Literature

The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool by Judson MA, et al. A Case Control Etiology of Sarcoidosis Study (ACCESS) sarcoidosis organ assessment instrument has been used for more than a decade to establish uniform standards for the probability of sarcoidosis organ involvement. The ACCESS instrument has become increasingly outdated as new technologies have been developed. Furthermore, the ACCESS instrument failed to address all possible organs involved with sarcoidosis. For these reasons, the World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) developed a new sarcoidosis organ assessment instrument. Various clinical manifestations were classified as highly probable, at least probable, possible, or indeterminate when no consensus could be reached. An instrument was developed by expert opinion that may be useful for the clinician and researcher in establishing criteria for sarcoidosis organ involvement. Read more ►

Pulmonology meets rheumatology in sarcoidosis: a review on the therapeutic approach by Drent M. et al. The pathogenesis of sarcoidosis is not fully elucidated. An exaggerated granulomatous reaction after exposure to unidentified antigens in genetically susceptible individuals evokes a clinical situation which we call sarcoidosis. Between 20 and 70% of patients need systemic therapy. No firm guidelines exist on whether, when, and how treatment should be started. Treatment is dependent on the presentation and the distribution, extensiveness and severity of sarcoidosis. Treatment of Löfgren's triad-related symptoms starts with NSAIDs; in other more extensive manifestations of sarcoidosis, the initiating dosage of glucocorticosteroids is approximately 20 mg daily. In terms of evidence-based treatment for sarcoidosis, only a few randomized controlled trials have been done. Identified associations of certain polymorphisms with severity of the disease and treatment response suggest future research questions as well as finding the cause(s) of sarcoidosis, and the elucidation of relevant biomarkers and new efficient treatments. The increased awareness of long-term side-effects of glucocorticosteroids and the emergence of new drugs have changed the treatment of sarcoidosis. Read more or View Video Abstract ►

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials by Lesley Ann Saketkoo, et al. Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack of consensus on appropriate outcome measures for reliably assessing treatment response. In the setting of connective tissue diseases (CTDs), some measures of ILD disease activity
and severity may be confounded by non-pulmonary comorbidities. Identification of consensus preliminary domains and instruments to measure them was attained and is a major advance anticipated to facilitate multicentre RCTs in the field. Read full paper ►

An official American Thoracic Society/European Respiratory Society Statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias by Travis WD et al by Travis WD et al. In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS) classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, and provided standardized terminology and diagnostic criteria. In addition, the historical "gold standard" of histologic diagnosis was replaced by a multidisciplinary approach. The objective of this statement is to update the 2002 ATS/ERS classification of IIPs. The clinical course of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia is recognized to be heterogeneous. Acute exacerbation of IIPs is now well defined. A substantial percentage of patients with IIP are difficult to classify, often due to mixed patterns of lung injury. A classification based on observed disease behavior is proposed for patients who are difficult to classify or for entities with heterogeneity in clinical course. This update is a supplement to the previous 2002 IIP classification document. It outlines advances in the past decade and potential areas for future investigation. Read more ►

Find all our selected literure, inluding archived pubmed selections, on our key papers page!



WASOG - World Association of Sarcoidosis and Other Granulomatous Disorders - WASOG, join wasog, wasog congresses, wasog meetings, wasog journal, wasog members, wasog history, wasog mission, wasog goals, wasog case report, wasog publications, wasog key papers